ArticleNeuropsychiatric disease and treatment2026
Neurocognitive and Psychiatric Outcomes Following Mild to Moderate COVID-19: A Longitudinal Comparison of Alpha/Delta and Omicron Variants.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Cognitive complaints are a core feature of post-acute sequelae of COVID-19 (PASC), yet less is known about combined neurocognitive and psychiatric outcomes following infection with later variants such as Omicron. This study compared longitudinal neuropsychological performance and psychiatric distress following mild to moderate COVID-19 infection during the Alpha/Delta versus Omicron periods. Patients and methods: Fifty-five adults with a history of mild to moderate COVID-19 infection participated in a longitudinal study. Participants infected during the Alpha/Delta waves (December 2020-November 2021; n = 27) were compared with those infected during the Omicron wave (February-May 2022; n = 28). Participants completed in-person neuropsychological assessments evaluating memory, processing speed, attention, and executive function, with impairment defined using standard clinical criteria. Psychiatric measures assessed symptoms of depression, anxiety, post-traumatic stress disorder (PTSD), and fatigue. Participants were reassessed approximately six months later. Group differences, comparisons to normative data, and longitudinal changes were analyzed. Results: At initial assessment, approximately half of participants in both groups demonstrated at least mild neuropsychological impairment. Both groups performed significantly below normative expectations on measures of immediate memory, while the Omicron group additionally showed reduced processing speed. No other cognitive domains differed from norms. At follow-up, impairment rates improved in both groups, and no test scores remained significantly below normative values; no participant demonstrated cognitive decline over time. Participants in the Alpha/Delta group reported more severe acute illness and greater medical comorbidity, though illness severity was mild to moderate in both groups. There were no significant between-group differences in depression, anxiety, PTSD, or fatigue. Conclusion: Neurocognitive performance improved over time following mild to moderate COVID-19 infection across both Alpha/Delta and Omicron variants, with no evidence of persistent deficits. Psychiatric distress and fatigue were similar across variants, suggesting generally favorable neuropsychiatric recovery trajectories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.